AFM
LSTA icon

Anson Funds Management’s Lisata Therapeutics LSTA Stock Holding History

Anson Funds Management’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,295
Closed -$143K – 397
2021
Q4 		$143K Buy
+11,295
New +$174K 0.01% 324
2021
Q1 		– Sell
-16,072
Closed -$345K – 278
2020
Q4 		$345K Buy
+16,072
New +$381K 0.07% 133

Other funds holding LSTA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Anson Funds Management's LSTA Position: Q1 2022 in Review

Anson Funds Management sold out of Lisata Therapeutics (LSTA) in Q1 2022, closing a stake of 11,295 shares — an estimated $143K sold.

Anson Funds Management first reported a position in LSTA in Q4 2020 and held it in 2 quarters. The position peaked at $345K in Q4 2020. 33 funds tracked by Wall St. Rank hold LSTA as of Q1 2022.

  • Anson Funds Management reported no remaining Lisata Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Anson Funds Management sold 11,295 Lisata Therapeutics shares in Q1 2022, an estimated $143K.
  • Anson Funds Management first reported a position in Lisata Therapeutics in Q4 2020 and held it in 2 quarters.
  • Anson Funds Management's Lisata Therapeutics position peaked at $345K in Q4 2020.
  • 33 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q1 2022.

Based on Anson Funds Management's 13F filing for Q1 2022, filed 12 May 2022.